AUB ScholarWorks

Gallotannin inhibits NFκB signaling and growth of human colon cancer xenografts

Show simple item record Al-Halabi R. Chedid M.B. Merhi R.A. El-Hajj H. Zahr H. Schneider-Stock R. Bazarbachi A. Gali-Muhtasib H.
dc.contributor.editor Jul-2011 2017-10-05T15:41:27Z 2017-10-05T15:41:27Z 2011
dc.identifier 10.4161/cbt.12.1.15715
dc.identifier.issn 15384047
dc.description.abstract Gallotannin (GT), the polyphenolic hydrolyzable tannin, exhibits anti-inflammatory and anticancer activities through mechanisms that are not fully understood. Several effects modulated by GT have been shown to be linked to interference with inflammatory mediators. Considering the central role of nuclear factor kappaB (NFκB) in inflammation and cancer, we investigated the effect of GT on NFκB signaling in HT-29 and HCT-116 human colon cancer cells. DNA binding assays revealed significant suppression of tumor necrosis factor (TNFα)-induced NFκB activation which correlated with the inhibition of IκBα phosphorylation and degradation. Sequentially, p65 nuclear translocation and DNA binding were inhibited. GT also downregulated the expression of NFκB-regulated inflammatory cytokines (IL-8, TNFα, IL-1α) and caused cell cycle arrest and accumulation of cells in pre-G1 phase. In vivo, GT (25 mg-kg body weight) injected intraperitoneally (i.p.) prior to or after tumor inoculation significantly decreased the volume of human colon cancer xenografts in NOD-SCID mice. GT-treated xenografts showed significantly lower microvessel density (CD31) as well as lower mRNA expression levels of IL-6, TNFα and IL-1α and of the proliferation (Ki-67) and angiogenesis (VEGFA) proteins, which may explain GTs in vivo anti-tumorigenic effects. Overall, our results indicate that the anti-inflammatory and antitumor activities of GT may be mediated in part through the suppression of NFκB activation. © 2011 Landes Bioscience.
dc.format.extent Pages: (59-68)
dc.language English
dc.publisher AUSTIN
dc.relation.ispartof Publication Name: Cancer Biology and Therapy; Publication Year: 2011; Volume: 12; no. 1; Pages: (59-68);
dc.source Scopus
dc.title Gallotannin inhibits NFκB signaling and growth of human colon cancer xenografts
dc.type Article
dc.contributor.affiliation Al-Halabi, R., Department of Biology, American University of Beirut, Beirut, Lebanon, Department of Biology, R. Hariri Campus, Lebanese University, Beirut, Lebanon
dc.contributor.affiliation Chedid, M.B., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Merhi, R.A., Department of Biology, R. Hariri Campus, Lebanese University, Beirut, Lebanon
dc.contributor.affiliation El-Hajj, H., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Zahr, H., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Schneider-Stock, R., Experimental Tumorpathology, Institut of Pathology University of Erlangen-Nürnberg, Universitätsstr. 22, Erlangen, Germany
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Gali-Muhtasib, H., Department of Biology, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Gali-Muhtasib, H.; Department of Biology, American University of Beirut, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Al-Halabi, R
dc.contributor.authorInitials Chedid, MB
dc.contributor.authorInitials Abou Merhi, R
dc.contributor.authorInitials El-Hajj, H
dc.contributor.authorInitials Zahr, H
dc.contributor.authorInitials Schneider-Stock, R
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorInitials Gali-Muhtasib, H
dc.contributor.authorReprintAddress Gali-Muhtasib, H (reprint author), Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
dc.contributor.authorResearcherID Schneider-Stock, Regine-H-8863-2012
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Al-Ayyoubi S, 2007, MOL CARCINOGEN, V46, P176, DOI 10.1002-mc.20252; Chen KS, 2009, LEUKEMIA RES, V33, P297, DOI 10.1016-j.leukres.2008.08.006; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038-sj-onc-1205240; Erdelyi K, 2005, MOL PHARMACOL, V68, P895, DOI 10.1124-mol.105.012518; Feldman KS, 2001, BIOORG MED CHEM LETT, V11, P1813, DOI 10.1016-S0960-894X(01)00332-8; Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857; Gali-Muhtasib HU, 2001, NUTR CANCER, V39, P108, DOI 10.1207-S15327914nc391_15; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038-nri2423; Hu HB, 2008, MOL CANCER THER, V7, P2681, DOI 10.1158-1535-7163.MCT-08-0456; Hu HB, 2009, CARCINOGENESIS, V30, P818, DOI 10.1093-carcin-bgp059; Iordachei S, 2010, J GASTROINTEST LIVER, V19, P135; KAUR M, 2011, CHEM-BIOL INTERACT, V15, P52; Kim MS, 2009, BIOL PHARM BULL, V32, P1053, DOI 10.1248-bpb.32.1053; Koleckar V, 2008, MINI-REV MED CHEM, V8, P436, DOI 10.2174-138955708784223486; Kuo PT, 2009, J AGR FOOD CHEM, V57, P3331, DOI 10.1021-jf803725h; Lee SJ, 2003, ARCH PHARM RES, V26, P832, DOI 10.1007-BF02980029; Li SH, 2007, MODERN PATHOL, V20, P497, DOI 10.1038-modpathol.3800762; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093-nar-gkq439; Nakamura Y, 2003, J AGR FOOD CHEM, V51, P331, DOI 10.1021-jf020847+; PERCHELLET JP, 1992, BASIC LIFE SCI, V59, P783; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038-nature02924; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007-s11010-009-0267-2; PTASZYNSKA MM, 2008, MOL CANCER RES, V3, P352; Rapizzi E, 2004, MOL PHARMACOL, V66, P890, DOI 10.1124-mol.104.000968; Serrano J, 2009, MOL NUTR FOOD RES, V53, P310; Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016-j.biocel.2006.03.023; YERUSHALMI R, 2010, LANCET ONCOL, V1, P174; Yoon JH, 2005, YONSEI MED J, V46, P585
dc.description.citedCount 10
dc.description.citedTotWOSCount 11
dc.description.citedWOSCount 11
dc.format.extentCount 10
dc.identifier.pubmedID 21532339
dc.identifier.scopusID 79959868265
dc.publisher.address 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
dc.relation.ispartOfISOAbbr Cancer Biol. Ther.
dc.relation.ispartOfIssue 1
dc.relation.ispartofPubTitle Cancer Biology and Therapy
dc.relation.ispartofPubTitleAbbr Cancer Biol. Ther.
dc.relation.ispartOfVolume 12
dc.source.ID WOS:000292290900006
dc.type.publication Journal
dc.subject.otherAuthKeyword Colon cancer
dc.subject.otherAuthKeyword Gallotannin
dc.subject.otherAuthKeyword Herbal medicine
dc.subject.otherAuthKeyword Inflammation
dc.subject.otherAuthKeyword NFκB
dc.subject.otherAuthKeyword Therapy
dc.subject.otherAuthKeyword Xenograft
dc.subject.otherChemCAS interleukin 8, 114308-91-7
dc.subject.otherChemCAS tannin, 1401-55-4
dc.subject.otherChemCAS I kappa B kinase, 209902-66-9
dc.subject.otherChemCAS Antigens, CD31
dc.subject.otherChemCAS Antineoplastic Agents, Phytogenic
dc.subject.otherChemCAS Cytokines
dc.subject.otherChemCAS Hydrolyzable Tannins
dc.subject.otherChemCAS I-kappa B Kinase,
dc.subject.otherChemCAS Inflammation Mediators
dc.subject.otherChemCAS Interleukin-1alpha
dc.subject.otherChemCAS Interleukin-6
dc.subject.otherChemCAS NF-kappa B
dc.subject.otherChemCAS NF-kappa B p50 Subunit
dc.subject.otherChemCAS NFKB1 protein, human
dc.subject.otherChemCAS RNA, Messenger
dc.subject.otherChemCAS Tumor Necrosis Factor-alpha
dc.subject.otherIndex CD31 antigen
dc.subject.otherIndex immunoglobulin enhancer binding protein
dc.subject.otherIndex interleukin 1alpha
dc.subject.otherIndex interleukin 6
dc.subject.otherIndex interleukin 8
dc.subject.otherIndex Ki 67 antigen
dc.subject.otherIndex messenger RNA
dc.subject.otherIndex synaptotagmin I
dc.subject.otherIndex tannin
dc.subject.otherIndex tumor necrosis factor alpha
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex autacoid
dc.subject.otherIndex CD31 antigen
dc.subject.otherIndex cytokine
dc.subject.otherIndex I kappa B kinase
dc.subject.otherIndex interleukin 1alpha
dc.subject.otherIndex interleukin 6
dc.subject.otherIndex messenger RNA
dc.subject.otherIndex NFKB1 protein, human
dc.subject.otherIndex tannin
dc.subject.otherIndex tumor necrosis factor alpha
dc.subject.otherIndex angiogenesis
dc.subject.otherIndex antiinflammatory activity
dc.subject.otherIndex antineoplastic activity
dc.subject.otherIndex article
dc.subject.otherIndex cancer growth
dc.subject.otherIndex cell cycle arrest
dc.subject.otherIndex cell cycle G1 phase
dc.subject.otherIndex cell proliferation
dc.subject.otherIndex cell strain HCT116
dc.subject.otherIndex cell strain HT29
dc.subject.otherIndex colon cancer
dc.subject.otherIndex controlled study
dc.subject.otherIndex DNA binding
dc.subject.otherIndex down regulation
dc.subject.otherIndex human
dc.subject.otherIndex human cell
dc.subject.otherIndex in vivo study
dc.subject.otherIndex protein degradation
dc.subject.otherIndex protein expression
dc.subject.otherIndex protein phosphorylation
dc.subject.otherIndex xenograft
dc.subject.otherIndex animal
dc.subject.otherIndex cell cycle
dc.subject.otherIndex colon tumor
dc.subject.otherIndex drug antagonism
dc.subject.otherIndex drug effect
dc.subject.otherIndex drug screening
dc.subject.otherIndex female
dc.subject.otherIndex genetics
dc.subject.otherIndex intraperitoneal drug administration
dc.subject.otherIndex metabolism
dc.subject.otherIndex microvasculature
dc.subject.otherIndex mouse
dc.subject.otherIndex nonobese diabetic mouse
dc.subject.otherIndex pathology
dc.subject.otherIndex signal transduction
dc.subject.otherIndex tumor cell line
dc.subject.otherIndex Animals
dc.subject.otherIndex Antigens, CD31
dc.subject.otherIndex Antineoplastic Agents, Phytogenic
dc.subject.otherIndex Cell Cycle
dc.subject.otherIndex Cell Line, Tumor
dc.subject.otherIndex Colonic Neoplasms
dc.subject.otherIndex Cytokines
dc.subject.otherIndex Female
dc.subject.otherIndex G1 Phase
dc.subject.otherIndex Humans
dc.subject.otherIndex Hydrolyzable Tannins
dc.subject.otherIndex I-kappa B Kinase
dc.subject.otherIndex Inflammation Mediators
dc.subject.otherIndex Injections, Intraperitoneal
dc.subject.otherIndex Interleukin-1alpha
dc.subject.otherIndex Interleukin-6
dc.subject.otherIndex Mice
dc.subject.otherIndex Mice, Inbred NOD
dc.subject.otherIndex Microvessels
dc.subject.otherIndex NF-kappa B
dc.subject.otherIndex NF-kappa B p50 Subunit
dc.subject.otherIndex RNA, Messenger
dc.subject.otherIndex Signal Transduction
dc.subject.otherIndex Tumor Necrosis Factor-alpha
dc.subject.otherIndex Xenograft Model Antitumor Assays
dc.subject.otherKeywordPlus NITRIC-OXIDE SYNTHASE
dc.subject.otherKeywordPlus INDUCED APOPTOSIS
dc.subject.otherKeywordPlus TANNIC-ACID
dc.subject.otherKeywordPlus IN-VITRO
dc.subject.otherKeywordPlus CELLS
dc.subject.otherKeywordPlus EXPRESSION
dc.subject.otherKeywordPlus INFLAMMATION
dc.subject.otherKeywordPlus REGULATORS
dc.subject.otherKeywordPlus CARCINOMA
dc.subject.otherKeywordPlus VIVO
dc.subject.otherWOS Oncology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account